Research Topics
| David R RappangeSummaryAffiliation: Erasmus University Country: The Netherlands Publications
|
Detail Information
Publications
Lifestyle intervention: from cost savings to value for moneyDavid R Rappange
Department of Health Policy and Management and Institute for Medical Technology Assessment, Erasmus University Medical Center, Rotterdam, Rotterdam, The Netherlands
J Public Health (Oxf) 32:440-7. 2010....
Healthcare costs and obesity prevention: drug costs and other sector-specific consequencesDavid R Rappange
Erasmus University Medical Centre, Department of Health Policy and Management and Institute for Medical Technology Assessment, Rotterdam, The Netherlands
Pharmacoeconomics 27:1031-44. 2009..Sector-specific financial consequences of preventing obesity are less well documented, for pharmaceutical spending as well as for other healthcare segments...
Back to the Consideration of Future Consequences Scale: time to reconsider?David R Rappange
Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University Medical Center, P O Box 1738, 3000DR, Rotterdam, The Netherlands
J Soc Psychol 149:562-84. 2009..From the findings, the authors raise questions regarding the construct validity of the CFC Scale, the interpretation of its results, and the usefulness of the CFC scale in its current form in applied research...
The evaluation of lifestyle interventions in the NetherlandsDavid R Rappange
Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
Health Econ Policy Law 7:243-61. 2012..Improvements of the decision-making framework in the Netherlands are required to guarantee sound evaluations of lifestyle interventions aimed at improving health...
Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?David R Rappange
Department of Health Policy and Management and Institute for Medical Technology Assessment, Erasmus University Medical Center, Rotterdam, The Netherlands
Pharmacoeconomics 26:815-30. 2008..We therefore conclude that the inclusion of unrelated medical costs should become the new standard...
